AstraZeneca Shares Drop 1.99% After ATTR-CM Trial Misses Endpoints, Nasdaq Futures Rise 0.94%
AZN•AstraZeneca shares plunged sharply at market open on July 9 after its Wainua ATTR-CM Phase 2b heart failure drug missed primary endpoints. The stock fell 1.99% despite a 0.94% gain in Nasdaq futures as chip shares and oil prices rebounded.
1. Wainua ATTR-CM Trial Failure
AstraZeneca’s Phase 2b trial for Wainua ATTR-CM in hereditary transthyretin amyloid cardiomyopathy failed to meet its primary endpoints, dashing hopes for a new heart failure therapy and surprising investors.
2. Share Price and Trading Reaction
At market open on July 9, AstraZeneca shares tumbled sharply, closing the session down 1.99% as market participants sold off on the unexpected trial outcome.
3. Broader Market Context
Despite the company’s setback, Nasdaq futures rose 0.94% driven by a rebound in chip sector stocks and higher oil prices, illustrating resilience in broader market trends.
